ATE494011T1 - Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen - Google Patents

Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen

Info

Publication number
ATE494011T1
ATE494011T1 AT04784440T AT04784440T ATE494011T1 AT E494011 T1 ATE494011 T1 AT E494011T1 AT 04784440 T AT04784440 T AT 04784440T AT 04784440 T AT04784440 T AT 04784440T AT E494011 T1 ATE494011 T1 AT E494011T1
Authority
AT
Austria
Prior art keywords
cell
myeloid
lipid
immune cells
drug formulations
Prior art date
Application number
AT04784440T
Other languages
English (en)
Inventor
Robert Gieseler
Guido Marquitan
Michael Scolaro
Sean Sullivan
Original Assignee
Rodos Biotarget Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rodos Biotarget Gmbh filed Critical Rodos Biotarget Gmbh
Application granted granted Critical
Publication of ATE494011T1 publication Critical patent/ATE494011T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
AT04784440T 2003-09-17 2004-09-17 Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen ATE494011T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50376903P 2003-09-17 2003-09-17
US56737604P 2004-04-30 2004-04-30
PCT/US2004/030578 WO2005027979A2 (en) 2003-09-17 2004-09-17 Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells

Publications (1)

Publication Number Publication Date
ATE494011T1 true ATE494011T1 (de) 2011-01-15

Family

ID=34381085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04784440T ATE494011T1 (de) 2003-09-17 2004-09-17 Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen

Country Status (8)

Country Link
US (3) US20050142114A1 (de)
EP (1) EP1663315B1 (de)
JP (1) JP2007505925A (de)
AT (1) ATE494011T1 (de)
CA (1) CA2539256C (de)
DE (1) DE602004030923D1 (de)
DK (1) DK1663315T3 (de)
WO (1) WO2005027979A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7233340B2 (en) * 2003-02-27 2007-06-19 Applied Imaging Corp. Linking of images to enable simultaneous viewing of multiple objects
US20070292494A1 (en) 2004-03-19 2007-12-20 Let There Be Hope Medical Research Institute Carbohydrate-Derivatized Liposomes for Targeting Cellular Carbohydrate Recognition Domains of Ctl/Ctld Lectins, and Intracellular Delivery of Therapeutically Active Compounds
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
US8138160B2 (en) * 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
JPWO2008026781A1 (ja) * 2006-08-31 2010-01-21 直人 奥 逆標的化脂質小胞体
TWI428135B (zh) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
US20110256213A1 (en) * 2008-10-15 2011-10-20 The Board Of Trustees Of The University Of Illinois Phospholipid micellar and liposomal compositions and uses thereof
WO2010141511A2 (en) * 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
WO2011109809A2 (en) * 2010-03-05 2011-09-09 New Agriculture, Inc A novel composition of matter for delivering lipid-soluble materials, and a method for producing it
EP2661495A4 (de) * 2011-01-05 2014-08-27 Us Agriculture Fusion von peptidoglycanhydrolase-enzymen an eine proteintransduktionsdomäne zur beseitigung von extrazellulären wie auch intrazellulären grampositiven pathogenen
WO2012133127A1 (ja) * 2011-03-31 2012-10-04 株式会社グライエンス ブドウ球菌属内の菌種を判別する方法
EP2638896A1 (de) 2012-03-14 2013-09-18 Bioneer A/S Kationisches liposomales Arzneimittelabgabesystem für spezifisches Targeting humaner CD14+ Monozyten in Vollblut
US20160145348A1 (en) * 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
WO2015041608A1 (en) * 2013-09-19 2015-03-26 Nanyang Technological University Methods for controlling assembly of lipids on a solid support
MX2018002090A (es) 2015-08-24 2018-09-12 Halo Bio Rnai Therapeutics Inc Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2018129270A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
EP3873532A1 (de) 2018-10-31 2021-09-08 Novartis AG Dc-sign-antikörper-arzneimittelkonjugate
US20230302154A1 (en) * 2020-08-19 2023-09-28 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
WO2024026452A1 (en) 2022-07-29 2024-02-01 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795739A (en) * 1987-05-29 1989-01-03 Gene Labs, Inc. Method of inhibiting HIV
JPH06504429A (ja) * 1990-10-09 1994-05-26 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド ウイルス複製の阻害
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
CA2270600A1 (en) * 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
CA2474056A1 (en) * 2002-01-24 2003-07-31 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
AU2003224725A1 (en) * 2002-03-20 2003-10-08 Brigham And Women's Hospital, Inc. Hiv therapeutic
WO2004064731A2 (en) * 2003-01-14 2004-08-05 University Of Washington Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues

Also Published As

Publication number Publication date
US20050142114A1 (en) 2005-06-30
US20160324779A1 (en) 2016-11-10
WO2005027979A3 (en) 2005-09-09
CA2539256C (en) 2012-04-24
US10357457B2 (en) 2019-07-23
US20140234400A1 (en) 2014-08-21
DE602004030923D1 (de) 2011-02-17
CA2539256A1 (en) 2005-03-31
EP1663315A2 (de) 2006-06-07
DK1663315T3 (da) 2011-04-18
EP1663315B1 (de) 2011-01-05
JP2007505925A (ja) 2007-03-15
WO2005027979A2 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
ATE494011T1 (de) Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen
Qian et al. TLR2 promotes glioma immune evasion by downregulating MHC class II molecules in microglia
Timaner et al. Therapy-educated mesenchymal stem cells enrich for tumor-initiating cells
Mullins et al. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
Wang et al. mRNA delivery of a bispecific single‐domain antibody to polarize tumor‐associated macrophages and synergize immunotherapy against liver malignancies
Cunha et al. The role of the inflammatory microenvironment in thyroid carcinogenesis
Zhang et al. Macrophage-derived IL-1α promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity
Cheng et al. Engineered mesenchymal stem cells for targeting solid tumors: therapeutic potential beyond regenerative therapy
Anz et al. Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression
Bansal et al. Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth
Yang et al. [Gd@ C82 (OH) 22] n nanoparticles induce dendritic cell maturation and activate Th1 immune responses
Dudek et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer
Ma Polarization of immune cells in the pathologic response to inhaled particulates
Herrmann et al. TLR9 is critical for glioma stem cell maintenance and targeting
Kobayashi et al. Halothane-induced liver injury is mediated by interleukin-17 in mice
Zhao et al. Intratumoral γδ T‐cell infiltrates, chemokine (C‐C Motif) ligand 4/chemokine (C‐C Motif) ligand 5 protein expression and survival in patients with hepatocellular carcinoma
Sim et al. IL2 variant circumvents ICOS+ regulatory T-cell expansion and promotes NK cell activation
Kyritsi et al. Mast cells induce ductular reaction mimicking liver injury in mice through mast cell–derived transforming growth factor beta 1 signaling
JP2016501013A (ja) γδＴ細胞の無ＩＬ−２増殖を誘導するための方法
Huang et al. Local stimulation of liver sinusoidal endothelial cells with a NOD1 agonist activates T cells and suppresses hepatitis B virus replication in mice
Subrahmanyam et al. Serum-dependent adhesion and cytotoxicity of cells to Litomosoides carinii microfilariae
Xu et al. Runx2 deficiency in osteoblasts promotes myeloma progression by altering the bone microenvironment at new bone sites
Roca et al. Inflammation and skeletal metastasis
Hu et al. A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model
Delforoush et al. In vitro and in vivo activity of melflufen (J1) in lymphoma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1663315

Country of ref document: EP